TCRR - TCR2 Therapeutics GAAP EPS of -$1.56 misses by $0.74
2023-03-23 07:59:00 ET
- TCR2 Therapeutics press release ( NASDAQ: TCRR ): Q4 GAAP EPS of -$1.56 misses by $0.74 .
- TCR² ended the fourth quarter of 2022 with $149.2 million in cash, cash equivalents, and investments compared to $265.6 million as of December 31, 2021.
For further details see:
TCR2 Therapeutics GAAP EPS of -$1.56 misses by $0.74